---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-047702"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:17:35.943609+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Surrozen reports FY2024 net loss of $63.6M; secures $76.4M financing for ophthalmology pipeline

## Summary
- Net loss $63.6M for 2024 vs $43.0M in 2023; Q4 net loss $28.0M.
- Cash $34.6M at 12/31/2024; received $76.4M gross proceeds from March 2025 financing.
- Collaboration revenue $10.0M for 2024, driven by Boehringer milestone; zero in 2023.
- R&D expenses $21.1M, down from $27.2M in 2023 due to restructuring and program discontinuation.
- Company prioritizing ophthalmology programs; Boehringer advancing SZN-413 toward clinical testing.

## SEC filing metadata
- accession: 0000950170-25-047702
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017025047702/0000950170-25-047702-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017025047702/srzn-20250331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-047702
- JSON: https://secwatch.observer/filing/0000950170-25-047702.json
- Plain text: https://secwatch.observer/filing/0000950170-25-047702.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.